7th Annual CAR-TCR Summit to Feature Presentation By Exacis Biotherapeutics CEO
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will present “Leveraging mRNA Based Gene Editing to Optimize Advancement of Safe and Cost-Effective IPSC Products” as part of the focus track on Innovations in Gene Engineering and Editing at the 7th Annual CAR-TCR Summit in Boston on September 19, 2022.
Exacis Biotherapeutics Included on Inside Precision Medicine’s Five RNA Therapeutics Startups to Watch in 2022 List
Five RNA Therapeutics Startups to Watch in 2022
Advanced Therapies Conference to Include Gene Modified Therapy Track – Exacis Biotherapeutics CEO to Participate in Panel Discussion
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will serve on a panel exploring the difference between autologous and allogeneic stem cell therapies during the Advanced Therapies Conference.
Cancer Progress Conference to Present Cost-Benefit Considerations for Complex Therapeutics- Panelists Include Exacis Biotherapeutics CEO
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will discuss strategies for optimal positioning of new therapies as a panel member at the Cancer Progress Conference.
Exacis Biotherapeutics CEO to Serve on Expert Panel at Longwood Healthcare Leaders Meeting
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will join of an expert panel of biotherapeutic leaders to discuss “Aligning Priorities with the Board” during the Longwood Healthcare Leaders Meeting.
Exacis Biotherapeutics Announces Strategic Partnership With CCRM For Specialty Manufacturing Of Services And Investment For Development Of iPSC-Derived mRNA-Engineered NK Cells
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis' innovative, iPSC-derived mRNA-engineered NK cell products to treat cancer. The partnership also includes a cash investment into Exacis by CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM, which will be used to fund operations.